Injectable Microspheres From Unsaturated Functionalized Polyhydric Alcohol Esters
    53.
    发明申请
    Injectable Microspheres From Unsaturated Functionalized Polyhydric Alcohol Esters 审中-公开
    来自不饱和官能化多元醇酯的注射微球

    公开(公告)号:US20070207213A1

    公开(公告)日:2007-09-06

    申请号:US11628650

    申请日:2005-06-16

    申请人: Chih-Chang Chu Da Wu

    发明人: Chih-Chang Chu Da Wu

    IPC分类号: A61K9/50 B01J13/04

    摘要: Injectable drug laden microspheres are obtained from unsaturated functionalized polyhydric alcohol ester of polyester by a method comprising dissolving the unsaturated functionalized ester in a hydrophobic organic solvent, dissolving drug and/or biologically active agent in water, admixing the two solutions to form water-in-oil emulsion, forming an aqueous solution of stabilizer, admixing the water-in-oil emulsion and the stabilizer solution to form water-in-oil-in-water emulsion, and evaporating the organic solvent.

    摘要翻译: 通过将不饱和官能化酯溶解在疏水性有机溶剂中,将药物和/或生物活性剂溶解在水中的方法,由聚酯的不饱和官能化多元醇酯得到可注射药物载体微球体,混合所述两种溶液, 油乳液,形成稳定剂水溶液,将油包水乳液和稳定剂溶液混合以形成水包油包水乳液,并蒸发有机溶剂。

    Injectable hydrogel microspheres from aqueous two-phase system
    54.
    发明申请
    Injectable hydrogel microspheres from aqueous two-phase system 有权
    注射水凝胶微球从水相两相体系

    公开(公告)号:US20060073281A1

    公开(公告)日:2006-04-06

    申请号:US10538477

    申请日:2003-12-04

    IPC分类号: B05D3/02

    摘要: Injectable hydrogel microspheres are prepared by forming an emulsion where hydrogel precursors are in a disperse aqueous phase and polymerizing the hydrogel precursors. In a preferred case, the hydrogel precursors are poly(ethylene glycol) diacrylate and N-isopropylacrylamide and the continuous phase of the emulsion is an aqueous solution of dextran and a dextran solubility reducer. The microspheres will load protein, e.g., cytokines, from aqueous solution.

    摘要翻译: 可注射的水凝胶微球通过形成其中水凝胶前体处于分散水相中并使水凝胶前体聚合的乳液来制备。 在优选的情况下,水凝胶前体是聚(乙二醇)二丙烯酸酯和N-异丙基丙烯酰胺,乳液的连续相是葡聚糖和葡聚糖溶解度降低剂的水溶液。 微球体将从水溶液中加载蛋白质,例如细胞因子。

    Hydrogel entrapping therapeutic agent and stent with coating comprising this
    55.
    发明授权
    Hydrogel entrapping therapeutic agent and stent with coating comprising this 失效
    水凝胶包埋治疗剂和含有该涂层的涂层的支架

    公开(公告)号:US06716445B2

    公开(公告)日:2004-04-06

    申请号:US10143572

    申请日:2002-05-13

    IPC分类号: A61K958

    摘要: A hydrogel forming system which comprises a hydrophobic macromer with unsaturated group terminated ends and a hydrophilic polymer which is a polysaccharide containing hydroxy groups which are reacted with unsaturated group introducing compound, is convertible by free radical polymerization to form a hydrogel containing a three dimensional crosslinked polymer network containing hydrophobic and hydrophilic components. Agent can be entrapped in the polymer network, e.g., drugs, macromolecules or synthetic or natural polymers, for controlled release therefrom. In one embodiment, a vascular stent is coated with hydrogel with therapeutic agent entrapped therein.

    摘要翻译: 包含具有不饱和基团末端的疏水大分子单体和亲水性聚合物的水凝胶形成体系,其是含有与不饱和基团导入化合物反应的羟基的多糖,可通过自由基聚合反应形成含有三维交联聚合物的水凝胶 网络含有疏水和亲水组分。 药剂可以被捕获在聚合物网络中,例如药物,大分子或合成或天然聚合物,用于从其中控制释放。 在一个实施方案中,血管支架用包封在其中的治疗剂的水凝胶包被。

    Dextran-maleic acid monoesters and hydrogels based thereon
    56.
    发明授权
    Dextran-maleic acid monoesters and hydrogels based thereon 有权
    基于其的葡聚糖 - 马来酸单酯和水凝胶

    公开(公告)号:US06476204B1

    公开(公告)日:2002-11-05

    申请号:US09743790

    申请日:2001-01-19

    IPC分类号: C07H1510

    摘要: Biodegradable hydrogels are formed by photocrosslinking dextran-maleic acid monoesters in which the average degree of substitution of each glucose unit of each &agr;-D-glucopyranosyl of dextran by maleic acid ranges from 0.60 to 1.6 and which have a weight average molecular weight ranging from 40,000 to 80,000 on a dextran basis. The hydrogels at pH 7 have maximum swelling ratios ranging from 500 to 1,500 percent. The hydrogels are characterized by increase in swelling ratio as average degree of substitution increases. The hydrogels are useful, for example, for drug delivery and solubility enhancers of drugs, as protective encapsulators of viruses used in gene therapy, and for conventional uses of hydrogels.

    摘要翻译: 通过光学交联葡聚糖 - 马来酸单酯形成可生物降解的水凝胶,其中马来酸对葡聚糖的每个α-D-吡喃葡萄糖基的每个葡萄糖单元的平均取代度为0.60-1.6,重均分子量为40,000 以葡聚糖为基准,达到80,000。 pH7的水凝胶具有最大的膨胀比范围为500至1,500%。 水凝胶的特征在于平均取代度增加溶胀比增加。 水凝胶可用于例如药物递送和药物溶解度增强剂,作为用于基因治疗的病毒的保护性封装剂和用于水凝胶的常规用途。

    Controlled release of doxorubicin
    57.
    发明授权
    Controlled release of doxorubicin 失效
    多柔比星的控制释放

    公开(公告)号:US06369037B1

    公开(公告)日:2002-04-09

    申请号:US09677859

    申请日:2000-10-03

    IPC分类号: A61K3170

    CPC分类号: A61K9/0024 A61K47/36

    摘要: A controlled release doxorubicin containing composition comprises doxorubicin physically entrapped in a dextran-methacrylate biodegradable hydrogel. The composition provides a rapid initial release of doxorubicin over a period of 5 to 7 hours followed by slow release. Increased degree of substitution in the dextran methacrylate decreases cumulative doxorubicin release. The composition provides higher cumulative release in acid pH (e.g., the stomach) than at physiological pH at lower degrees of substitution. The composition allows administration alternatives to the bolus intravenous and continuous intravenous methods of administration now used for doxorubicin. The composition can be prepared without the use of heat (which can result in heat destruction of doxorubicin) and is prepared without chemical cross-linker such as glutaraldehyde and the toxicity associated therewith.

    摘要翻译: 含有控释的多柔比星含有组合物包括物质包埋在葡聚糖 - 甲基丙烯酸甲酯可生物降解的水凝胶中的多柔比星。 该组合物在5至7小时期间提供阿霉素的快速初始释放,随后缓慢释放。 甲基葡聚糖甲基丙烯酸酯中的增加的取代度降低了多柔比星的释放。 组合物在酸性pH(例如胃)中提供比在较低取代度下在生理pH下更高的累积释放。 该组合物允许给予药物替代用于多柔比星的静脉内和连续静脉注射方法。 可以在不使用热的情况下制备组合物(其可导致多柔比星的热破坏),并且在没有化学交联剂如戊二醛和与其相关的毒性的情况下制备。